Bamco Inc. NY lifted its position in Nevro (NYSE:NVRO) by 42.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 30,300 shares of the medical equipment provider’s stock after acquiring an additional 9,000 shares during the quarter. Bamco Inc. NY owned approximately 0.10% of Nevro worth $2,626,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of the stock. OppenheimerFunds Inc. increased its stake in Nevro by 50.0% in the 4th quarter. OppenheimerFunds Inc. now owns 900,594 shares of the medical equipment provider’s stock valued at $62,177,000 after buying an additional 300,064 shares during the period. First Manhattan Co. acquired a new position in Nevro in the 4th quarter valued at approximately $15,630,000. Jennison Associates LLC increased its stake in Nevro by 12.6% in the 4th quarter. Jennison Associates LLC now owns 1,282,874 shares of the medical equipment provider’s stock valued at $88,570,000 after buying an additional 143,962 shares during the period. BlackRock Inc. increased its stake in Nevro by 5.2% in the 4th quarter. BlackRock Inc. now owns 2,616,753 shares of the medical equipment provider’s stock valued at $180,662,000 after buying an additional 130,320 shares during the period. Finally, Amundi Pioneer Asset Management Inc. increased its stake in Nevro by 285.1% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 160,040 shares of the medical equipment provider’s stock valued at $11,049,000 after buying an additional 118,486 shares during the period.
Shares of Nevro opened at $72.64 on Tuesday, according to Marketbeat.com. Nevro has a 12 month low of $65.00 and a 12 month high of $94.34. The firm has a market cap of $2.19 billion, a PE ratio of -58.11 and a beta of -0.52. The company has a current ratio of 7.99, a quick ratio of 6.17 and a debt-to-equity ratio of 0.61.
Nevro (NYSE:NVRO) last announced its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.01). Nevro had a negative return on equity of 16.32% and a negative net margin of 11.53%. The business had revenue of $97.96 million for the quarter, compared to analyst estimates of $96.87 million. During the same quarter last year, the company earned ($0.34) EPS. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year. equities research analysts forecast that Nevro will post -1.2 earnings per share for the current fiscal year.
NVRO has been the topic of several research reports. Goldman Sachs initiated coverage on shares of Nevro in a research note on Wednesday, April 4th. They issued a “neutral” rating and a $83.00 price objective on the stock. ValuEngine upgraded shares of Nevro from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. JMP Securities reiterated an “overweight” rating and issued a $105.00 price objective (down previously from $120.00) on shares of Nevro in a research note on Tuesday, May 8th. Zacks Investment Research upgraded shares of Nevro from a “sell” rating to a “hold” rating in a research note on Thursday, April 26th. Finally, Wells Fargo lowered shares of Nevro from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 8th. Three analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. Nevro has a consensus rating of “Hold” and a consensus price target of $98.78.
In other news, Director Wilfred E. Jaeger sold 14,458 shares of the stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $83.28, for a total transaction of $1,204,062.24. Following the transaction, the director now owns 1,518 shares in the company, valued at approximately $126,419.04. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Wilfred E. Jaeger sold 10,000 shares of the stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $80.48, for a total transaction of $804,800.00. Following the transaction, the director now owns 1,518 shares in the company, valued at approximately $122,168.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 241,116 shares of company stock worth $19,446,802. 6.90% of the stock is currently owned by company insiders.
Nevro Company Profile
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro (NYSE:NVRO).
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.